Timo Soeterik

25 General Introduction and Thesis Outline 39. Feng TS, Sharif-Afshar AR, Wu J, et al. Multiparametric MRI Improves Accuracy of Clinical Nomograms for Predicting Extracapsular Extension of Prostate Cancer. Urology . 2015;86:332-337. 40. Rayn KN, Bioom JB, Gold SA, et al. Added Value of Mult iparametric Magnet ic Resonance lmaging to Clinical Nomograms tor Predicting Adverse Pathology in Prostate Cancer sr. J Urol . 2019;200:1041-1047. 41. McClelland JC. The early diagnosis of cancer in the bladder, prostate and kidney. Can Med Assoc J . 1934;31:165-167. 42. Butler SS, Muralidhar V, Zhao SG, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate- specific antigen screening in 2012. Cancer . 2020;126:717-724. 43. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol . 2014;65:1046-1055. 44. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol . 2015;33:272-277. 45. Carlsson S, Benfante N, Alvim R, et al. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. J Urol . 2020;203:1122-1127. 46. Jeffrey J. Tosoian, H. Ballentine Carter, Abbey Lepor and SL. Active Surveillance for Prostate Cancer: Contemporary State of Practice. Nat Rev Urol . 2016;116:1477-1490. 47. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stageT1c) prostate cancer. J AmMed Assoc . 1994;271:368-374. 48. Donin NM, Laze J, Zhou M et al. Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. Urology . 2013;82:148-153. 49. Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J. Long- term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. Eur Urol . 2016;70:760-766. 50. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol . 2013;64:876-892. 51. Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov D V. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. J Urol . 2016;196:721-726. 52. Sant eon . Zorg Voor Ui t koms t . Uitkomstindicatoren Voor Kanker. Resultaten Santeon Ziekenhuizen. 2014. 53. Evans SM, Millar JL, Moore CM, et al. Cohort profile: The TrueNTH Global Registry - An international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open . 2017;7(11):e017006. 54. Martini A, Gupta A, Lewis SC, et al. Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. BJU Int. 2018;122:1025-1033. 1